Physiological levels of Pik3caH1047R mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Tikoo, Anjali ^a,b   Roh, Vincent ^a   Montgomery, Karen G ^a   Ivetac, Ivan ^a   Waring, Paul ^b   Pelzer, Rebecca ^a   Hare, Lauren ^a,c   Shackleton, Mark ^a,b   Humbert, Patrick ^a,b   Phillips, Wayne A ^a,b,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOMA; BREAST FIBROADENOMA; BREAST SARCOMA; CARCINOGENESIS; CELL LABELING; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE FREQUENCY; GENE INDUCTION; GENE MUTATION; HETEROZYGOSITY; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MAMMARY GLAND; MORPHOGENESIS; MOUSE; NONHUMAN; ONCOGENE; PIK3CA GENE; PROMOTER REGION; ALLELE; ANIMAL; CHEMISTRY; ENZYMOLOGY; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENE TARGETING; GENETICS; GROWTH, DEVELOPMENT AND AGING; HYPERPLASIA; METABOLISM; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; UDDER;

MUS;

ALLELES; ANIMALS; BASE SEQUENCE; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCK-IN TECHNIQUES; HYPERPLASIA; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MOLECULAR SEQUENCE DATA; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROMOTER REGIONS, GENETIC;

EID: 84861634733     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036924     Document Type: Article

References (50)

1. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, et al. (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64: 7678-7681.
2. Samuels Y, Velculescu VE, (2004) Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3: 1221-1224.
3. Samuels Y, Waldman T, (2010) Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol 347: 21-41.
4. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, et al. (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3: 772-775.
5. Li H, Zhu R, Wang L, Zhu T, Li Q, et al. (2010) PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast. Exp Mol Pathol 88: 150-155.
6. Dunlap J, Le C, Shukla A, Patterson J, Presnell A, et al. (2010) Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat 120: 409-418.
7. Miron A, Varadi M, Carrasco D, Li H, Luongo L, et al. (2010) PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res 70: 5674-5678.
8. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB, (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004.
9. Lai YL, Mau BL, Cheng WH, Chen HM, Chiu HH, et al. (2008) PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol 15: 1064-1069.
10. Li SY, Rong M, Grieu F, Iacopetta B, (2006) PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 96: 91-95.
11. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, et al. (2009) PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15: 5049-5059.
12. Saal LH, Holm K, Maurer M, Memeo L, Su T, et al. (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65: 2554-2559.
13. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, et al. (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68: 6084-6091.
14. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, et al. (2010) PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A 107: 10208-10213.
15. Whyte DB, Holbeck SL, (2006) Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. Biochem Biophys Res Commun 340: 469-475.
16. Wang L, Zhang Q, Zhang J, Sun S, Guo H, et al. (2011) PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer 11: 11: 248.
17. Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, et al. (2011) Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat 128: 447-456.
18. Bozhanov SS, Angelova SG, Krasteva ME, Markov TL, Christova SL, et al. (2010) Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer. J Cancer Res Clin Oncol 136: 1657-1669.
19. Bader AG, Kang S, Vogt PK, (2006) Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A 103: 1475-1479.
20. Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, et al. (2005) Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65: 10992-11000.
21. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, et al. (2005) The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A 102: 18443-18448.
22. Adams JR, Xu K, Liu JC, Agamez NM, Loch AJ, et al. (2011) Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. Cancer Res 71: 2706-2717.
23. Liu P, Cheng H, Santiago S, Raeder M, Zhang F, et al. (2011) Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med 17: 1116-1120.
24. Meyer DS, Brinkhaus H, Muller U, Muller M, Cardiff RD, et al. (2011) Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. Cancer Res 71: 4344-4351.
25. Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, et al. (2000) PIK3CA as an oncogene in cervical cancer. Oncogene 19: 2739-2744.
26. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, et al. (1999) PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21: 99-102.
27. Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, et al. (2004) Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5: 375-387.
28. Kinross KM, Montgomery KG, Kleinschmidt M, Waring P, Ivetac I, et al. (2012) An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest.
29. Wagner KU, McAllister K, Ward T, Davis B, Wiseman R, et al. (2001) Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Res 10: 545-553.
30. Wagner KU, Wall RJ, St-Onge L, Gruss P, Wynshaw-Boris A, et al. (1997) Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res 25: 4323-4330.
31. Friedrich G, Soriano P, (1991) Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice. Genes Dev 5: 1513-1523.
32. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, et al. (2006) Generation of a functional mammary gland from a single stem cell. Nature 439: 84-88.
33. Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, et al. (2007) Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 9: 201-209.
34. Karantza-Wadsworth V, White E, (2008) A mouse mammary epithelial cell model to identify molecular mechanisms regulating breast cancer progression. Methods Enzymol 446: 61-76.
35. Spike BT, Dirlam A, Dibling BC, Marvin J, Williams BO, et al. (2004) The Rb tumor suppressor is required for stress erythropoiesis. EMBO J 23: 4319-4329.
36. Zhang H, Liu G, Dziubinski M, Yang Z, Ethier SP, et al. (2008) Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells. Breast Cancer Res Treat 112: 217-227.
37. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, et al. (2010) BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 7: 403-417.
38. Bocker W, Moll R, Poremba C, Holland R, Van Diest PJ, et al. (2002) Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest 82: 737-746.
39. Liu BY, McDermott SP, Khwaja SS, Alexander CM, (2004) The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. Proc Natl Acad Sci U S A 101: 4158-4163.
40. Li Y, Welm B, Podsypanina K, Huang S, Chamorro M, et al. (2003) Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci U S A 100: 15853-15858.
41. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, et al. (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15: 907-913.
42. Lu P, Ewald AJ, Martin GR, Werb Z, (2008) Genetic mosaic analysis reveals FGF receptor 2 function in terminal end buds during mammary gland branching morphogenesis. Dev Biol 321: 77-87.
43. Parsa S, Ramasamy SK, De Langhe S, Gupte VV, Haigh JJ, et al. (2008) Terminal end bud maintenance in mammary gland is dependent upon FGFR2b signaling. Dev Biol 317: 121-131.
44. Renner O, Blanco-Aparicio C, Grassow M, Canamero M, Leal JF, et al. (2008) Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation. Cancer Res 68: 9643-9653.
45. Sebastian J, Richards RG, Walker MP, Wiesen JF, Werb Z, et al. (1998) Activation and function of the epidermal growth factor receptor and erbB-2 during mammary gland morphogenesis. Cell Growth Differ 9: 777-785.
46. Kim D, Dressler GR, (2007) PTEN modulates GDNF/RET mediated chemotaxis and branching morphogenesis in the developing kidney. Dev Biol 307: 290-299.
47. Tang MJ, Cai Y, Tsai SJ, Wang YK, Dressler GR, (2002) Ureteric bud outgrowth in response to RET activation is mediated by phosphatidylinositol 3-kinase. Dev Biol 243: 128-136.
48. Hutchinson J, Jin J, Cardiff RD, Woodgett JR, Muller WJ, (2001) Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 21: 2203-2212.
49. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, et al. (2009) AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16: 21-32.
50. Youssef KK, Van Keymeulen A, Lapouge G, Beck B, Michaux C, et al. (2010) Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol 12: 299-305.